New Drug for Advanced Lung Cancer

	Tweet

The U.S. Food and Drug Administration has granted fast-track approval to Tarceva (erlotinib) to treat advanced non-small cell lung cancer that has failed to respond to other therapy.

Similar drugs include AstraZeneca’s lung cancer drug Iressa and ImClone Systems’ colon cancer drug Erbitux, both of which try to block a protein that encourages cancer cell growth. The FDA said clinical trials involving 731 patients showed Tarceva appeared to extend life by approximately two months, from an average of 4.7 months among those who took a placebo to 6.7 months. Similar drugs in this class have only been proven to shrink tumors, according to The New York Times.

Tarceva and other so-called targeted drugs tend to have fewer side effects than other cancer treatments, although there have been infrequent reports of serious lung disease among some Tarceva users. Other side effects could include diarrhea, rash, and nausea. And the drug could cause fetal harm to pregnant women, the FDA said.

Non-small cell lung cancer is the most common form of lung cancer in the United States, accounting for 80 percent of cases, the agency said. It noted that it granted approval for Tarceva less than a year after makers OSI Pharmaceuticals and Genentech Inc. submitted the first part of their application in January.

RELATED STORIES:
Different Types Of Lung Cancer   Targeted cancer drug fails to help patients - study   Lancet calls for big jump in global cigarette tax   New Treatment Offers Hope to Lung Cancer Patients   Diabetes not tied to increased lung cancer risk   Gulf War veterans may face increased risk of lung cancer   Lung cancer ‘different in women’   NY jury awards $17.1 million in sick smoker case   Symptoms often felt long before lung cancer found   Spontaneous smoking cessation may be an early symptom of lung cancer, research suggests   False-positive cancer screening results costly   How Is Lung Cancer Treated?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]